Pieris Pharmaceuticals (PIRS) Stock Price, News & Analysis

Company Overview

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $15.59 to $16.25
• 50-Day Range: $15.44 to $17.30
• 52-Week Range: $6.20 to $22.32
• Volume: 8,045 shs
• Average Volume: 37,842 shs
• Market Capitalization: $21.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Pieris Pharmaceuticals Stock Analysis - MarketRank™

Pieris Pharmaceuticals scored higher than 33% of companies evaluated by MarketBeat, and ranked 815th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Pieris Pharmaceuticals.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Pieris Pharmaceuticals is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pieris Pharmaceuticals is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pieris Pharmaceuticals has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.70% of the float of Pieris Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Pieris Pharmaceuticals has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pieris Pharmaceuticals has recently decreased by 16.04%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pieris Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Pieris Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.81

Percentage of Shares Shorted

1.70% of the float of Pieris Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Pieris Pharmaceuticals has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pieris Pharmaceuticals has recently decreased by 16.04%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.21

News Sentiment

Pieris Pharmaceuticals has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Pieris Pharmaceuticals this week, compared to 0 articles on an average week.

MarketBeat Follows

Only 1 people have added Pieris Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pieris Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.39% of the stock of Pieris Pharmaceuticals is held by insiders.

Percentage Held by Institutions

40.11% of the stock of Pieris Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PIRS Stock Analysis - Frequently Asked Questions

How have PIRS shares performed this year?

Pieris Pharmaceuticals' stock was trading at $14.56 at the beginning of 2024. Since then, PIRS stock has increased by 10.0% and is now trading at $16.01.
View the best growth stocks for 2024 here.

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) issued its earnings results on Tuesday, November, 2nd. The biotechnology company reported ($19.20) EPS for the quarter, hitting the consensus estimate of ($19.20). The biotechnology company had revenue of $4.06 million for the quarter, compared to the consensus estimate of $7.98 million. Pieris Pharmaceuticals had a negative trailing twelve-month return on equity of 80.93% and a negative net margin of 39.71%.

When did Pieris Pharmaceuticals' stock split?

Pieris Pharmaceuticals's stock reverse split on Tuesday, April 23rd 2024. The 1-80 reverse split was announced on Tuesday, April 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Who are Pieris Pharmaceuticals' major shareholders?

Pieris Pharmaceuticals' top institutional investors include BML Capital Management LLC (3.19%) and Frazier Life Sciences Management L.P. (1.21%). Insiders that own company stock include Adar1 Capital Management, Llc, Christopher P Kiritsy and Tim Demuth.
View institutional ownership trends.

How do I buy shares of Pieris Pharmaceuticals?

Shares of PIRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Pieris Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pieris Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CymaBay Therapeutics (CBAY), Adobe (ADBE), General Electric (GE) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 11/02/2021
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PIRS
• CUSIP: N/A
• CIK: 1583648
• Web: www.pieris.com
• Phone: (857) 246-8998
• Fax: 49-8161-141-1444
• Employees: 140
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($12.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-24,540,000.00
• Net Margins: -39.71%
• Pretax Margin: -1,179.96%
• Return on Equity: -80.93%
• Return on Assets: -59.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.82
• Quick Ratio: 4.82

Sales & Book Value

• Annual Sales: $42.81 million
• Price / Sales: 0.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.32 per share
• Price / Book: 1.30

Miscellaneous

• Outstanding Shares: 1,320,000
• Free Float: 1,236,000
• Market Cap: $21.13 million
• Optionable: Optionable
• Beta: 0.66